Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies

episode

CME in Minutes: Education in Dermatology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury (Hour 2) 40 min · 24 Sep 2026 · Rahimi & Grote Show

Cubs squander chance to clinch playoff berth in losing to Marlins, 3-2 (Hour 1) 42 min · 24 Sep 2026 · Rahimi & Grote Show

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury 19 min · 24 Sep 2026 · Rahimi & Grote Show

The AWP: HR Without the Drama: Handbooks, Hard Conversations & Documentation 57 min · 24 Sep 2026 · EyeCode Media

710: That New Mouse Pad Feeling 2h 13m · 24 Sep 2026 · Accidental Tech Podcast

Steven Bartlett REVEALS the Secret Behind the World’s Fastest Growing Podcast | PBD Podcast #861 1h 27m · 24 Sep 2026 · PBD Podcast

Report any issue

Source

Recorded29 May 2025

Publisherc.answersincme.com ↗

Handlerec:1447283

Show notes

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in